Tarsus Pharmaceuticals, Inc. (TARS)
After hours:
| Previous Close | 33.71 |
| Open | 33.98 |
| Bid | 32.69 x 200 |
| Ask | 32.80 x 200 |
| Day's Range | 32.41 - 34.35 |
| 52 Week Range | 12.57 - 40.40 |
| Volume | |
| Avg. Volume | 732,154 |
| Market Cap | 1.229B |
| Beta (5Y Monthly) | 1.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.62 |
| Earnings Date | May 07, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.38 |
GlobeNewswireTarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP. Tarsus has elected to draw $75 million on the closing date, April 19, 2024, with the remaining $125 million of committed capital avai
Simply Wall St.Insider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14%
Insiders who bought Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) stock lover the last 12 months are probably not as...
ZacksWall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 47.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
